

Additional Information



V001

Part 1 - Summary of the dossier



V002

1 - Table of Contents



T004

1a Administrative Information



T005

1a1 Additional Information



T006

1a2 Cover letter



T007

1a3 Decision of Foreign Authorities



T008

1a4 Documentation on product quality



T009

1a5 Forms



T010

Other Forms



C027

1a6 Manufacturing



T028

1b Summary of Product Characteristics, Label and Package Insert



T029

1c1 DACS on the quality documentation



V006

1c2 DACS on the safety documentation



T093

1c3 DACS on the efficacy documentation



V008

1c Critical expert reports



V044

1c1 Critical expert report on the quality documentation



V054

1c2 Critical expert report on the safety documentation



V045

1c3 Critical expert report on the efficacy documentation



V055

Responses to Swissmedic LoQ



V009

2 - Table of Contents



T035

Part 2 - quality documentation



V010

2a Product description



V046

2a Qualitative and quantitative particulars of the constituents



V011

2b Description of the manufacturing method



V012

2c Control of starting material



V013

2c1 Active substance(s)



V014

2c2 Excipient(s)



V015

2c3 Container closure system



V016

2c4 Substances of biological origin



V017

2c Production and control of starting materials



V047

2c1 Starting materials listed in pharmacopoeias



T095

2c2 Starting materials not listed in a pharmacopoeia



T096

2d Control tests carried out at intermediate stages of the production process



V018

2d Control tests during the manufacturing process



T097

2e Control tests on the finished products



V019

2f Batch-to-batch consistency



T098

2f Stability tests



V020

2f1 Stability tests on active substances



V021

2f2 Stability tests on the finished products



V022

2g Other information



V023

2g Stability test



T099

2h Other information



T100

3 - Table of Contents



T079

Part 3 – Safety and residues



V024

3a General requirements



T101

3a Safety



V025

3a1 Precise identification of the product and of its active substance(s)



V026

3a2 Pharmacological studies



V027

3a3 Toxicological studies



V028

3a4 Other requirements



V029

3a5 User safety



V030

3a6 Environmental risk assessment



V031

3b Pre-clinical studies



V049

3b Residues



V032

3b1 Precise identification of the product concerned by the application



V033

3b2 Metabolism and residue kinetics



V034

3b3 Residue analytical method



V035

3c Clinical trials



V050

3d Environmental risk assessment)



T104

3e Assessment required for VMPs containing or consisting of GMOs



T105

3e Annexes



T106

3f Residue tests to be included in the pre-clinical studies



V048

4 - Table of Contents



T092

Part 4 – Pre-clinical and clinical trials



V036

4a General requirements



T107

4a Pre-clinical trials



V037

4a1 Pharmacology



V038

4a2 Development of resistance



V039

4a3 Dose determination and confirmation



V051

4a4 Tolerance in the target animal species



V052

4b Clinical trials



V041

4b Pre-clinical studies



V053

4c Clinical trials



V056